AAN Poster
2025 AAN Poster:
INTERCEPT-AD Biomarker Results: Early effect of sabirnetug treatment on synaptic biomarkers in Alzheimer’s disease
AAN Presentation
2025 AAN Presentation:
ALTITUDE-AD: Use of Plasma pTau217 Assay to Screen Potential Participants in an Ongoing Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease
ADPD 2025 Poster
2025 ADPD Poster:
Utility of Human iPSC-derived Neuronal Model for Evaluating Synaptic Binding of Aβ Oligomers
ADPD 2025 Poster
2025 ADPD Poster:
Preparing Stable Monomeric Aβ to Assess AβO Selectivity Assays
ADPD 2025 Presentation
2025 ADPD:
Sabirnetug overview and use of a pTau217 Assay as a Marker of Amyloid Burden for Screening Participants in an Ongoing Phase 2 Study, ALTITUDE-AD.
2025 APDD Summit
2025 APDD Summit:
Sabirnetug overview and use of a pTau217 Assay as a Marker of Amyloid Burden for Screening Participants in an Ongoing Phase 2 Study, ALTITUDE-AD
2025 JPAD
2025 JPAD:
Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer’s disease
2025 JPAD
2025 JPAD:
INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer’s disease
